Pharma BD Deal Intelligence
A $1B bet on a niche renal drug that grew into an $861M/year blockbuster franchise before genericizing on a normal patent-cliff timeline — a real win that later got absorbed into the much larger Sanofi-Genzyme deal.
Full analysis, sources & comparables →Deal terms: 0.7272 Genzyme General shares or $47.50 cash per GelTex share (27% premium); Renagel projected to reach $500M in 5 years and $1B within a decade.
Genzyme General acquires GelTex Pharmaceuticals for $1 billion in a tax-free transaction; GelTex holders receive 0.7272 Genzyme shares or $47.50 cash per…
Genzyme launches Renvela (sevelamer carbonate) in the US for dialysis patients — the next-generation reformulation of the GelTex-acquired Renagel franchise,…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Genzyme General acquired GelTex Pharmaceuticals in a stock deal valued at ~$1.0B (based on 21.4M GelTex shares and Genzyme's $65.31 close on Sep 8). Brought Renagel and WelChol marketed products plus a polymer drug platform. Closed Dec 14, 2000.
A $1B bet on a niche renal drug that grew into an $861M/year blockbuster franchise before genericizing on a normal patent-cliff timeline — a real win that later got absorbed into the much larger Sanofi-Genzyme deal.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genzyme General (Genzyme Corporation) / GelTex Pharmaceuticals Inc. (this deal) | 2000 | $1.0B | 79 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2000 deals · Cardiovascular deals